Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
7
×
life sciences
national blog main
boston top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
clinical trials
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
fda
medicare
pfizer
spark therapeutics
abbvie
alnylam pharmaceuticals
amgen
amicus therapeutics
cancer
cystic fibrosis
deals
diagnostics
What
drug
7
×
patients
7
×
fda
bio
roundup
approved
developers
disease
help
market
new
pfizer
sets
therapy
acorda
acquisitions
advantages
ago
akcea
albert
alnylam
amyloidosis
aren’t
attr
available
bar
battle
biggest
bourla
brings
cancer
ceo
company
cope
crispr
daunting
debilitating
drugs
eisai
episodes
Language
unset
unknown
Current search:
drug
×
patients
×
" boston blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets